Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients
Status:
Recruiting
Trial end date:
2028-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label, randomized, multicentric study in patients with high-risk non-muscle
invasive bladder cancer who had never received BCG for this disease.
The objective is to evaluate the efficacy of atezolizumab as measured by recurrence-free
survival.